Ovid Therapeutics Inc OVID
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OVID is a good fit for your portfolio.
News
-
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
-
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
-
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $3.21
- Day Range
- $3.17–3.29
- 52-Week Range
- $2.57–4.14
- Bid/Ask
- $3.06 / $3.23
- Market Cap
- $228.39 Mil
- Volume/Avg
- 176,642 / 212,979
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 578.38
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.ovidrx.com
Comparables
Valuation
Metric
|
OVID
|
PLRX
|
CBAY
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.58 | 1.63 | 12.65 |
Price/Sales | 578.38 | 477.92 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
OVID
PLRX
CBAY
Financial Strength
Metric
|
OVID
|
PLRX
|
CBAY
|
---|---|---|---|
Quick Ratio | 9.22 | 17.43 | 10.70 |
Current Ratio | 9.55 | 17.72 | 10.96 |
Interest Coverage | — | −145.34 | −5.27 |
Quick Ratio
OVID
PLRX
CBAY
Profitability
Metric
|
OVID
|
PLRX
|
CBAY
|
---|---|---|---|
Return on Assets (Normalized) | −33.42% | −22.68% | −30.06% |
Return on Equity (Normalized) | −42.55% | −24.50% | −51.97% |
Return on Invested Capital (Normalized) | −40.93% | −28.46% | −30.87% |
Return on Assets
OVID
PLRX
CBAY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kxgcwwdd | Bfvc | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mrnrynjp | Jrqtrns | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rdpzllsd | Pkpyjq | $98.1 Bil | |
MRNA
| Moderna Inc | Wdysqkg | Wjqm | $39.1 Bil | |
ARGX
| argenx SE ADR | Zvsypmgbz | Dpvp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Rvqgwsqhl | Zysp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jqmlshh | Mtlnlmk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fysglfgm | Ryvmcz | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xqhkbcrrt | Wptqc | $12.5 Bil | |
INCY
| Incyte Corp | Zrvlvwfn | Dfcsgt | $11.9 Bil |